Paramsothy Sudarshan, Borody Thomas J, Lin Enmoore, Finlayson Sarah, Walsh Alissa J, Samuel Douglas, van den Bogaerde Johan, Leong Rupert W L, Connor Susan, Ng Watson, Mitchell Hazel M, Kaakoush Nadeem, Kamm Michael A
*Department of Gastroenterology and Hepatology, St Vincent's Hospital, Sydney, Australia; †Department of Gastroenterology and Hepatology, Bankstown Lidcombe Hospital, Sydney, Australia; ‡Department of Gastroenterology and Hepatology, Nambour General Hospital, Nambour, Australia; §School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, Australia; ‖Centre for Digestive Diseases, Sydney, Australia; ¶Department of Gastroenterology and Hepatology, Liverpool Hospital, Sydney, Australia; **Department of Gastroenterology and Hepatology, St Vincent's Hospital Melbourne and University of Melbourne, Melbourne, Australia; and ††Imperial College London, London, United Kingdom.
Inflamm Bowel Dis. 2015 Jul;21(7):1600-6. doi: 10.1097/MIB.0000000000000405.
Increasing demand for fecal microbiota transplantation (FMT) has created a need for stool banks sourced from long-term healthy donors. Here, we describe our experience in recruiting and screening fecal donors.
Mailbox, newspaper, and online advertisements were used. Potential donors were required to satisfy a prescreen telephone conversation, pass blood and stool investigations, then undertake a screening interview including medical history, physical examination, and evaluation of donor selection criteria.
One hundred sixteen potential donors were prescreened of whom 74 failed-47 declined based on study donation requirements (primarily related to frequency and duration of donations), 13 had medical comorbidities, 6 variant Creutzfeldt-Jakob disease risk factors, 8 for other reasons. Thirty-eight completed stool and blood testing-1 failed blood testing (indeterminate hepatitis C serology), whereas 15 failed stool investigations (5 Dientamoeba fragilis, 5 Blastocystis hominis, 1 B. hominis and D. fragilis, 1 Giardia intestinalis plus D. fragilis, 1 Norovirus plus Clostridium difficile toxin positive, and 2 leucocytes or erythrocytes on stool microscopy). Of the 18 potential donors proceeding to screening interview, 6 were excluded (3 body mass index >30, 1 illicit drug use, 1 uncontrolled anxiety and concerns regarding compliance, 1 irregular bowel movements after new medication commencement). In total, only 12 of 116 (10%) potential donors were enrolled as study donors.
Recruitment of fecal donors for FMT is challenging with only a small percentage ultimately serving as donors. Many were unable or unwilling to meet the donor commitment requirements. A surprisingly large proportion of healthy asymptomatic donors failed stool testing, primarily due to gastrointestinal parasites.
对粪便微生物群移植(FMT)的需求不断增加,这就需要建立来自长期健康供体的粪便库。在此,我们描述了我们在招募和筛选粪便供体方面的经验。
采用邮箱、报纸和在线广告。潜在供体需通过预筛选电话交谈,通过血液和粪便检查,然后进行筛选面谈,包括病史、体格检查和供体选择标准评估。
对116名潜在供体进行了预筛选,其中74名未通过筛选——47名因研究捐赠要求(主要与捐赠频率和持续时间有关)而拒绝,13名有合并症,6名有变异型克雅氏病风险因素,8名因其他原因未通过。38名完成了粪便和血液检测——1名血液检测未通过(丙型肝炎血清学结果不确定),而15名粪便检查未通过(5名脆弱双核阿米巴、5名结肠小袋纤毛虫、1名结肠小袋纤毛虫和脆弱双核阿米巴、1名肠贾第虫加脆弱双核阿米巴、1名诺如病毒加艰难梭菌毒素阳性,以及2名粪便显微镜检查发现白细胞或红细胞)。在进行筛选面谈的18名潜在供体中,6名被排除(3名体重指数>30,1名使用非法药物,1名焦虑未得到控制且担心依从性,1名开始使用新药后排便不规律)。总共116名潜在供体中只有12名(10%)被招募为研究供体。
招募用于FMT的粪便供体具有挑战性,最终只有一小部分人成为供体。许多人无法或不愿意满足供体承诺要求。健康无症状供体中未通过粪便检测的比例惊人地高,主要原因是胃肠道寄生虫。